Premium
Clinical Pharmacogenetics Implementation Consortium ( CPIC ) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR 1 or CACNA 1S Genotypes
Author(s) -
Gonsalves Stephen G.,
Dirksen Robert T.,
Sangkuhl Katrin,
Pulk Rebecca,
Alvarellos Maria,
Vo Teresa,
Hikino Keiko,
Roden Dan,
Klein Teri E.,
Poler S. Mark,
Patel Sephalie,
Caudle Kelly E.,
Gordon Ronald,
Brandom Barbara,
Biesecker Leslie G.
Publication year - 2019
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1319
Subject(s) - context (archaeology) , malignant hyperthermia , ryanodine receptor , anesthetic , presumption , volatile anesthetic , medicine , pharmacogenetics , pharmacology , anesthesia , chemistry , biology , gene , calcium , genotype , biochemistry , paleontology , political science , law
The identification in a patient of 1 of the 50 variants in the RYR1 or CACNA1S genes reviewed here should lead to a presumption of malignant hyperthermia susceptibility (MHS). MHS can lead to life-threatening reactions to potent volatile anesthetic agents or succinylcholine. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of these agents in patients with these RYR1 or CACNA1S variants (updates at https://cpicpgx.org/guidelines and www.pharmgkb.org).